Watson completes Actavis acquisition, anticipates over $8B in 2012 revenue


Watson Pharmaceuticals announced that it has completed the acquisition of the Actavis Group for EUR4.25B. The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8B. Additionally, Watson continues to see $300M in annual cost synergy savings from the Actavis acquisition within three years.

View Comments (0)